InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.41
(
0.46%
)
Bitcoin
62,635.03
(
-0.83%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: bladerunner1717 post# 156997

Friday, 02/15/2013 10:48:27 PM

Friday, February 15, 2013 10:48:27 PM

Post# of 252311

5. CDX1135 complement inhibitor:
- inhibits all complement activation pathways and this differentiates it from Soliris which is limited to C5 complement pathway
My own 2 cents worth on 1135 in DDD:
- since this is an ultra-orphan indication, initial trial will be in less than a dozen pts
- if initial trial positive, 1135 will go into an Accelerated Approval trial (this is similar to the development pathway for Soliris)

No word on when we could see initial PoC data for CDX1135?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up